Literature DB >> 28327329

Ocrelizumab in multiple sclerosis: markers and mechanisms.

Reinhard Hohlfeld1, Edgar Meinl2.   

Abstract

Entities:  

Year:  2017        PMID： 28327329     DOI： 10.1016/S1474-4422(17)30048-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  9 in total

Review 1.  Multiple Sclerosis: B Cells Take Center Stage.

Authors:  Anne-Katrin Pröbstel; Stephen L Hauser
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

2.  Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.

Authors:  Marina Boziki; Christos Bakirtzis; Styliani-Aggeliki Sintila; Evangelia Kesidou; Evdoxia Gounari; Aliki Ioakimidou; Vasiliki Tsavdaridou; Lemonia Skoura; Asimina Fylaktou; Vasiliki Nikolaidou; Maria Stangou; Ioannis Nikolaidis; Virginia Giantzi; Eleni Karafoulidou; Paschalis Theotokis; Nikolaos Grigoriadis
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

Review 3.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 4.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

Review 5.  Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.

Authors:  Joachim Havla; Reinhard Hohlfeld
Journal:  Neurotherapeutics       Date:  2022-03-14       Impact factor: 6.088

6.  In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.

Authors:  Rune A Høglund; Andreas Lossius; Jorunn N Johansen; Jane Homan; Jūratė Šaltytė Benth; Harlan Robins; Bjarne Bogen; Robert D Bremel; Trygve Holmøy
Journal:  Front Immunol       Date:  2017-10-02       Impact factor: 7.561

7.  Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.

Authors:  Darius Häusler; Silke Häusser-Kinzel; Linda Feldmann; Sebastian Torke; Gildas Lepennetier; Claude C A Bernard; Scott S Zamvil; Wolfgang Brück; Klaus Lehmann-Horn; Martin S Weber
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-07       Impact factor: 11.205

Review 8.  Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.

Authors:  Madeline Bross; Melody Hackett; Evanthia Bernitsas
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

9.  Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.

Authors:  Samuel Alsén; Jakob Cervin; Yaxiong Deng; Louis Szeponik; Ulf Alexander Wenzel; Joakim Karlsson; Helena Cucak; Megan Livingston; David Bryder; Qianjin Lu; Bengt Johansson-Lindbom; Ulf Yrlid
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.